Vyvanse and Hyperventilation - a phase IV clinical study of FDA data

Summary:

Hyperventilation is reported as a side effect among people who take Vyvanse (lisdexamfetamine dimesylate), especially for people who are female, 10-19 old, have been taking the drug for < 1 month also take Xyrem, and have Affective disorder.

The phase IV clinical study analyzes which people have Hyperventilation when taking Vyvanse. It is created by eHealthMe based on reports of 28,083 people who have side effects when taking Vyvanse from the FDA, and is updated regularly.

What is Vyvanse?

Vyvanse has active ingredients of lisdexamfetamine dimesylate. It is often used in attention deficit hyperactivity disorder. eHealthMe is studying from 35,863 Vyvanse users. Check the latest studies of Vyvanse.

What is Hyperventilation?

Hyperventilation is found to be associated with 760 drugs and 1,444 conditions by eHealthMe. Check the latest studies of Hyperventilation.

On May, 07, 2026

28,083 people reported to have side effects when taking Vyvanse.
Among them, 17 people (0.06%) have Hyperventilation.

Among these 17 people:

* Approximation only. Some reports may have incomplete information.

Do you take Vyvanse and have Hyperventilation?

- Check whether Hyperventilation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Vyvanse:

Vyvanse (35,863 reports)

Hyperventilation treatments and more:

Hyperventilation (8,309 reports)

How severe was Hyperventilation and when was it recovered:

Hyperventilation in Vyvanse

Expand to all the drugs that have ingredients of lisdexamfetamine dimesylate:

Hyperventilation and drugs with ingredients of lisdexamfetamine dimesylate (18 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Vyvanse:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperventilation:

Hyperventilation (760 drugs)

Browse all the conditions that are associated with Hyperventilation:

Hyperventilation (1,444 conditions)

Related publications that referenced our studies

Najib J, Wimer D, Zeng J, Lam KW, Romanyak N, Paige Morgan E, Thadavila A, "Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder", Journal of central nervous system disease, 2017 Aug .
Maneeton N, Maneeton B, Suttajit S, Reungyos J, Srisurapanont M, Martin SD, "Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD", Drug design, development and therapy, 2017 Jan .
Maneeton B, Maneeton N, Likhitsathian S, Suttajit S, Narkpongphun A, Srisurapanont M, Woottiluk P, "Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials", Drug design, development and therapy, 2013 Jan .
Najib J, Wimer D, Zeng J, Lam KW, Romanyak N, Paige Morgan E, Thadavila A, "Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder", Journal of central nervous system disease, 2017 Aug .
Maneeton N, Maneeton B, Suttajit S, Reungyos J, Srisurapanont M, Martin SD, "Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD", Drug design, development and therapy, 2017 Jan .
Maneeton B, Maneeton N, Likhitsathian S, Suttajit S, Narkpongphun A, Srisurapanont M, Woottiluk P, "Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials", Drug design, development and therapy, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on lisdexamfetamine dimesylate (the active ingredients of Vyvanse) and Vyvanse (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.